A price war has hit India’s weight-loss and diabetes drug market after semaglutide lost patent protection, pushing innovator Novo Nordisk to cut prices of Ozempic and Wegovy. Cheaper generics may widen access, but concerns over misuse are rising, prompting regulatory scrutiny.
Recent Posts
- ‘God Bless Them All’: Iran President, Foreign Minister Appear In Tehran Crowd Even As War Escalates — Watch Video
- ‘Easy To Be Cynical’: Radhika Gupta Rebuts Shankar Sharma’s ‘Brainwashed’ Jibe At SIP Investors
- Google Pixel 11 Pro Renders Leak: New Camera Design, Slimmer Build And Specs Revealed
- IMD Issues Rain Warning: Maharashtra, Telangana, Karnataka Among States To See Impact — Full Forecast
- ‘Laughing Stock’: Fans Lambast Italy For Failing To Qualify For FIFA World Cup For Third Straight Time